Antun Sablek
Antun Sablek is an associate principal in the Life Sciences Practice. He advises clients on pharmaceutical policy issues at both the European and global levels, with particular expertise in EU health technology assessment (HTA) implementation, intellectual property and access frameworks, and industrial policy related to innovation and competitiveness.
Antun works with biopharmaceutical companies, diagnostics firms, and industry trade associations to assess policy developments and their implications for innovation, access, and stakeholder engagement. He supports government affairs and policy teams by developing robust analytical content and shaping positions on key legislative and regulatory initiatives.
He has led and contributed to influential reports commissioned by EFPIA and EuropaBio, covering topics such as incentives for R&D investment, access to novel therapies, and the sustainability of the pharmaceutical innovation ecosystem. His work spans both cross-cutting issues and therapy-specific policy challenges in areas such as oncology and rare diseases.
Antun has presented findings at EU-level stakeholder events, participated in public consultations, and contributed to multi-stakeholder dialogues aimed at advancing evidence-based policy in life sciences. Known for his thoughtful approach and ability to bridge technical and policy perspectives, he is a trusted partner for clients navigating dynamic policy environments.